Advertisement


Lalan S. Wilfong, MD, on Metastatic Solid Tumors: Limiting Low-Value Care

2018 ASCO Quality Care Symposium

Advertisement

Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.



Related Videos

Issues in Oncology

Monika K. Krzyzanowska, MD, MPH, on Quality Improvement: Avoiding the Pitfalls

Monika K. Krzyzanowska, MD, MPH, of Princess Margaret Cancer Centre, summarized the Keynote Lecture, including the points that clinicians should carefully plan their quality improvement projects, understand the barriers to quality, and ensure their efforts are sustainable.

Supportive Care

Jeremy Warner, MD, on Patient Navigation: Weathering the Storm of Cancer Care

Jeremy Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses the ways in which patient navigators affect cancer care and how patients benefit.

Thyroid Cancer

Lauren P. Wallner, PhD, MPH, on Thyroid Cancer: Reducing Overtreatment With Radioactive Iodine

Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings from a population-based study, which showed that many patients believe they had no choice about whether or not to receive radioactive iodine, even though it often does not improve survival. There is a need, she says, for better shared decision-making (Abstract 159).

Issues in Oncology
Symptom Management
Pain Management

Angela M. Stover, PhD, on Patient-Reported Symptoms: Results From the STAR and PRO-TECT Trials

Angela M. Stover, PhD, of the University of North Carolina at Chapel Hill, discusses study findings on ways to alert clinicians when patients signal symptoms such as pain or diarrhea that may be cause for concern (Abstract 158).

Issues in Oncology
Cost of Care

Aaron Lyss, MBA, on Getting the Highest-Value Quality Intervention

Aaron Lyss, MBA, of Tennessee Oncology, discusses ways that clinicians and patients can employ the most cost- and treatment-effective measures, clinical trials, and incident learning systems.

Advertisement

Advertisement




Advertisement